
## John M Flack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8418606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recruitment, Retention, and Future Direction for a Heart Health Education and Risk Reduction Intervention Led by Community Health Workers in an African American Majority City. Journal of Racial and Ethnic Health Disparities, 2023, 10, 1432-1440.	3.2	2
2	Vitamin K status, all-cause mortality, and cardiovascular disease in adults with chronic kidney disease: the Chronic Renal Insufficiency Cohort. American Journal of Clinical Nutrition, 2022, 115, 941-948.	4.7	9
3	Race and Antihypertensive Drug Therapy: Edging Closer to a New Paradigm. Hypertension, 2022, 79, 349-351.	2.7	3
4	Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 601-611.	6.1	8
5	Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. Hypertension, 2021, 77, 72-81.	2.7	13
6	Angiotensin onverting enzyme inhibitors increase antiâ€fibrotic biomarkers in African Americans with left ventricular hypertrophy. Journal of Clinical Hypertension, 2021, 23, 1008-1016.	2.0	6
7	Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney International, 2021, 100, 1292-1302.	5.2	22
8	Better Implementation of What Is Known Will Reverse Falling Hypertension Control Rates: We Know How to Reverse Falling Hypertension Rates. Hypertension, 2021, 78, 588-590.	2.7	5
9	Blood pressure and the new ACC/AHA hypertension guidelines. Trends in Cardiovascular Medicine, 2020, 30, 160-164.	4.9	274
10	Response to "COVID-19 and ACEI/ARB: Not Associated?― American Journal of Hypertension, 2020, 33, 789-790.	2.0	2
11	Effect of Lower Blood Pressure Goals on Left Ventricular Structure and Function in Patients With Subclinical Hypertensive Heart Disease. American Journal of Hypertension, 2020, 33, 837-845.	2.0	4
12	Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial. American Journal of Hypertension, 2020, 33, 528-533.	2.0	3
13	Hypertension and COVID-19. American Journal of Hypertension, 2020, 33, 373-374.	2.0	260
14	The ACC/AHA and ESC/ESH Hypertension Guidelines: Contrasting Versions of Idiosyncratic Excellence. American Journal of Hypertension, 2019, 32, 705-708.	2.0	0
15	Prevalence of refractory hypertension in the United States from 1999 to 2014. Journal of Hypertension, 2019, 37, 1797-1804.	0.5	27
16	The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. American Journal of Hypertension, 2018, 31, 133-135.	2.0	48
17	Insights on βâ€blockers for the treatment of hypertension: A survey of health care practitioners. Journal of Clinical Hypertension, 2018, 20, 1464-1472.	2.0	6
18	Predicting the risk of apparent treatment-resistant hypertension: a longitudinal, cohort study in an urban hypertension referral clinic. Journal of the American Society of Hypertension, 2018, 12, 809-817.	2.3	2

John M Flack

#	Article	IF	CITATIONS
19	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension, 2018, 72, e53-e90.	2.7	629
20	Method of Blood Pressure Measurement, Interpretation of SPRINT, and the Atlantic Divide. Current Hypertension Reports, 2017, 19, 19.	3.5	5
21	Update From the Editors to Our Readers. American Journal of Hypertension, 2017, 30, 1-2.	2.0	0
22	The Case for Low Blood Pressure Targets. American Journal of Hypertension, 2017, 30, 3-7.	2.0	15
23	Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic) Tj ETQq1 1 545-553.	0.784314 1.9	rgBT /Overloo 29
24	A Novel Approach for Estimating Cost-Effectiveness of Pharmacological Treatment in Drug NaÃ⁻ve Adults with Hypertension. American Journal of Hypertension, 2016, 29, 1138-1139.	2.0	0
25	Asâ€needed intravenous antihypertensive therapy and blood pressure control. Journal of Hospital Medicine, 2016, 11, 193-198.	1.4	28
26	Reducing Health Inequities in the U.S Journal of the American College of Cardiology, 2016, 68, 517-524.	2.8	36
27	Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction. Journal of the American Society of Hypertension, 2016, 10, 906-916.	2.3	33
28	The Authors Reply, "asâ€needed intravenous antihypertensive therapy and blood pressure control― Journal of Hospital Medicine, 2016, 11, 526-526.	1.4	0
29	Do We Need a New Definition of Hypertension After SPRINT?. American Journal of Hypertension, 2016, 29, 1127-1129.	2.0	16
30	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease. Hypertension, 2016, 67, 387-396.	2.7	134
31	SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. American Journal of Hypertension, 2016, 29, 2-4.	2.0	29
32	A preliminary experimental examination of worldview verification, perceived racism, and stress reactivity in African Americans Health Psychology, 2016, 35, 366-375.	1.6	44
33	Blood pressure treatment and outcomes in hypertensive patients without acute target organ damage: a retrospective cohort. American Journal of Emergency Medicine, 2015, 33, 1219-1224.	1.6	49
34	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension, 2015, 9, 769-779.	2.3	36
35	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	2.2	458
36	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	27.0	1,848

John M Flack

#	Article	IF	CITATIONS
37	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. Journal of the American College of Cardiology, 2014, 64, 1071-1078.	2.8	164
38	Clinical Effect of Naturally Random Allocation to Lower Systolic Blood Pressure Beginning Before the Development of Hypertension. Hypertension, 2014, 63, 1182-1188.	2.7	68
39	Catheterâ€Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTNâ€3 Trial. Clinical Cardiology, 2012, 35, 528-535.	1.8	278
40	Relationship of Resistant Hypertension and Treatment Outcomes With Total Arterial Compliance in a Predominantly African American Hypertensive Cohort. Journal of Clinical Hypertension, 2012, 14, 618-622.	2.0	13
41	Management of High Blood Pressure in Blacks. Hypertension, 2010, 56, 780-800.	2.7	398
42	Epidemiology and Unmet Needs in Hypertension. Journal of Managed Care Pharmacy, 2007, 13, 2-8.	2.2	15
43	Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. Vascular Health and Risk Management, 2007, 3, 1029-37.	2.3	19
44	Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology, 2003, 41, 1148-1155.	2.8	214
45	Epidemiology of Hypertension and Cardiovascular Disease in African Americans. Journal of Clinical Hypertension, 2003, 5, 5-11.	2.0	99
46	Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment. Journal of the American Society of Nephrology: JASN, 2003, 14, S92-S98.	6.1	70
47	Hypertension in special populations. Cardiology Clinics, 2002, 20, 303-319.	2.2	27
48	Cardiovascular disease costs associated with uncontrolled hypertension. Managed Care Interface, 2002, 15, 28-36.	0.2	36
49	Ethnicity and Renal Disease: Lessons From the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. American Journal of Kidney Diseases, 1993, 21, 31-40.	1.9	100
50	Influence of Obesity on Blood Pressure Responses to Antihypertensive Drug Therapy in an Urban Hypertension Specialty Clinic. American Journal of Hypertension, 0, , .	2.0	1